ASCLETIS ANNOUNCES POSITIVE TOPLINE RESULTS FROM U.S. PHASE II, 24-WEEK STUDY FOR ITS ULTRA-LONG-ACTING SUBCUTANEOUS DEPOT FORMULATIONS OF SMALL MOLECULE GLP-1R AGONIST ASC30 FOR OBESITY
ASCLETIS PHARMA INC - ASC30 ACHIEVES 7.5% PLACEBO-ADJUSTED MEAN WEIGHT LOSS AT WEEK 16 AFTER THREE MONTHLY DOSES
ASCLETIS PHARMA INC - ASC30 DEMONSTRATES SAFETY PROFILE CONSISTENT WITH GLP-1 DRUG CLASS
ASCLETIS PHARMA INC - ASC30 MAINTAINS WEIGHT LOSS FOR FOUR MONTHS AFTER FINAL MONTHLY DOSE
ASCLETIS PHARMA INC - NO DISCONTINUATIONS DUE TO ADVERSE EVENTS FOR ASC30 OR PLACEBO
ASCLETIS PHARMA INC: ASC30 PHASE II STUDY ACHIEVED ITS PRIMARY ENDPOINT
Source text: ID:nPn4ZwWQ3a
Further company coverage: 1672.HK
((Reuters.Briefs@thomsonreuters.com;))
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.